Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
BLTE
$186.15
$
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Next Earnings
2026-02-25
Beta
-1.461
Average Volume
Market Cap
Last Dividend
CIK
0001889109
ISIN
US07782B1044
CUSIP
07782B104
CEO
Yu-Hsin Lin
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
25
IPO Date
2022-04-29
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| China Universal Asset Management Co. Ltd. Acquires New Position in Belite Bio, Inc. Sponsored ADR $BLTE | China Universal Asset Management Co. Ltd. bought a new position in shares of Belite Bio, Inc. Sponsored ADR (NASDAQ: BLTE) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 5,000 shares of the company's stock, valued at approximately $370,000. Several | Defense World | 2026-02-22 04:36:57 |
| High Net Worth Advisory Group LLC Invests $259,000 in Belite Bio, Inc. Sponsored ADR $BLTE | High Net Worth Advisory Group LLC acquired a new stake in shares of Belite Bio, Inc. Sponsored ADR (NASDAQ: BLTE) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 3,500 shares of the company's stock, valued at approximately $259,000. A | Defense World | 2026-01-19 04:54:45 |
| Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares | SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has priced an underwritten public offering of 2,272,727 American Depositary Shares (“ADSs”), each representing one of its ordinary shares, at a public offering price of $154.00 per ADS. The Company has also granted the underwriters a 30-day option to purchase up to 340,909 additional ADSs from the Company at the public offering price, less underwriting discounts and commissions. The gross proceeds of the offering to the Company are expected to be approximately $350.0 million before deducting underwriting discounts and commissions and offering expenses payable by Belite Bio. All of the securities in the offering are to be sold by Belite Bio. The closing of the offering is expected to occur on or about December 3, 2025, subject to the satisfaction of customary closing conditions. | GlobeNewsWire | 2025-12-01 22:37:00 |
| Why Belite Bio Stock Soared on Monday | The biotech's Stargardt disease drug did well in a late-stage clinical trial. This is an eye affliction that can lead to loss of central vision. | The Motley Fool | 2025-12-01 18:45:34 |
| Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares | SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has commenced an underwritten public offering of American Depositary Shares (“ADSs”), each representing one of its ordinary shares. All of the securities in the offering are to be sold by Belite Bio. In addition, Belite Bio intends to grant the underwriters a 30-day option to purchase additional ADSs at the public offering price, less underwriting discounts and commission. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. | GlobeNewsWire | 2025-12-01 16:20:00 |
| Belite Bio, Inc (BLTE) Discusses Positive Topline Results from Phase III DRAGON Trial of Tinlarebant in Stargardt Disease Transcript | Belite Bio, Inc (BLTE) Discusses Positive Topline Results from Phase III DRAGON Trial of Tinlarebant in Stargardt Disease Transcript | Seeking Alpha | 2025-12-01 14:23:25 |
| Belite Bio Scores First Successful Phase 3 Trial For Rare Vision-Loss Disease | Belite Bio Inc. (NASDAQ: BLTE) on Monday released topline results from the global Phase 3 DRAGON trial of Tinlarebant, marking the first successful pivotal trial in patients with Stargardt disease type 1 (STGD1). | Benzinga | 2025-12-01 09:14:33 |
| Belite Bio's drug for genetic eye disease meets main goal in late-stage trial | Belite Bio said on Monday that its experimental drug for a rare genetic eye disease met the main goal in a late-stage study. | Reuters | 2025-12-01 06:09:15 |
| New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease | SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”) today announced topline results from the global Phase 3 “DRAGON” trial of Tinlarebant, marking the first successful pivotal trial in patients with Stargardt disease type 1 (STGD1). STGD1 is an eye disease that leads to progressive vision loss, usually beginning in childhood or young adulthood, and currently has no approved treatment worldwide. | GlobeNewsWire | 2025-12-01 06:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| S-8 | 2026-01-30 | 2026-01-30 | View Filing |
| 6-K | 2026-01-27 | 2026-01-27 | View Filing |
| SC 13G | 2025-12-10 | 2025-12-10 | View Filing |
| 424B5 | 2025-12-02 | 2025-12-02 | View Filing |
| 6-K | 2025-12-02 | 2025-12-02 | View Filing |
| 424B5 | 2025-12-01 | 2025-12-01 | View Filing |
| 6-K | 2025-12-01 | 2025-12-01 | View Filing |
| 6-K | 2025-12-01 | 2025-12-01 | View Filing |
| 6-K | 2025-12-01 | 2025-12-01 | View Filing |
| 6-K | 2025-11-10 | 2025-11-10 | View Filing |
| F-3ASR | 2025-10-22 | 2025-10-22 | View Filing |
| 6-K | 2025-09-08 | 2025-09-08 | View Filing |
| 6-K | 2025-08-11 | 2025-08-11 | View Filing |
| 424B5 | 2025-08-08 | 2025-08-08 | View Filing |
| 6-K | 2025-08-07 | 2025-08-07 | View Filing |
| 6-K | 2025-07-02 | 2025-07-02 | View Filing |
| 6-K | 2025-05-21 | 2025-05-21 | View Filing |
| 6-K | 2025-05-14 | 2025-05-13 | View Filing |
| 6-K | 2025-04-15 | 2025-04-15 | View Filing |
| 6-K | 2025-03-28 | 2025-03-28 | View Filing |
| S-8 | 2025-03-21 | 2025-03-21 | View Filing |
| 6-K | 2025-03-18 | 2025-03-18 | View Filing |
| 6-K | 2025-03-17 | 2025-03-17 | View Filing |
| 6-K | 2025-03-17 | 2025-03-17 | View Filing |
| 20-F | 2025-03-17 | 2025-03-17 | View Filing |
| 6-K | 2025-02-27 | 2025-02-27 | View Filing |
| 424B5 | 2025-02-07 | 2025-02-07 | View Filing |
| 6-K | 2025-02-06 | 2025-02-06 | View Filing |
| 424B7 | 2025-01-27 | 2025-01-27 | View Filing |
| F-3ASR | 2025-01-27 | 2025-01-27 | View Filing |
| SC 13G | 2025-01-21 | 2025-01-21 | View Filing |
| SC 13G | 2025-01-21 | 2025-01-21 | View Filing |
| 6-K | 2024-11-04 | 2024-11-04 | View Filing |
| S-8 | 2024-10-01 | 2024-10-01 | View Filing |
| 6-K | 2024-09-03 | 2024-09-03 | View Filing |
| 6-K | 2024-08-09 | 2024-08-09 | View Filing |
| 6-K | 2024-05-14 | 2024-05-13 | View Filing |
| 424B5 | 2024-04-29 | 2024-04-29 | View Filing |
| 6-K | 2024-04-26 | 2024-04-25 | View Filing |
| 6-K | 2024-03-22 | 2024-03-22 | View Filing |
| 6-K | 2024-03-12 | 2024-03-11 | View Filing |
| 20-F | 2024-03-12 | 2024-03-11 | View Filing |
| 6-K | 2024-03-12 | 2024-03-11 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Keltner Channel Strategy | 64.75% | 1.03 | 198 | 0.08 | 0.26 | 30.35 |
| Swarm Intelligence Strategy | 60.32% | 1 | 690 | 0.03 | 0.08 | 25.93 |
| Adaptive Wave | 52.90% | 1.62 | 3 | 0.03 | 0.07 | 18.5 |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | x |
| xxxxxxxxx | xxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxx | xxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxx | xxxxxxxx% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | x | x | xxxx |
| xxx | xxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |